AbstractA patient experiencing chronic New York Heart Association (NYHA) Class III heart failure with reduced left ventricular ejection fraction and signs of right ventricular dysfunction is treated with baroreflex activation therapy (BAT). Despite optimal medical therapy, the patient had repeatedly decompensated and was approaching a refractory terminal stage. BAT chronically reduced muscle sympathetic nerve activity and dramatically improved clinical presentation of the patient to NYHA Class I through 12 months of therapy. BAT may hold promise for patients with advanced heart failure and reduced ejection fraction who have exhausted conventional therapy options.<Learning objective: Activation of the baroreflex via stimulation of the caroti...
Abstract Baroreflex activation therapy (BAT) is a possible adjuvant treatment for patients with hear...
AbstractObjectivesThe objective of this clinical trial was to assess the safety and efficacy of caro...
There has been significant interest in research for the development of device-based therapy as a tre...
AbstractA patient experiencing chronic New York Heart Association (NYHA) Class III heart failure wit...
Background: Prognosis in advanced heart failure with reduced ejection fraction (HFrEF) remains poor ...
The progression of heart failure with reduced ejection fraction is promoted by sympathovagal imbalan...
Heart failure is promoted by the imbalance of sympathovagal, which increased sympathetic and decreas...
Background: Baroreflex activation therapy (BAT) exerts in severe heart failure sympathoinhibitory ef...
Background: Autonomic imbalance characterized by sympathetic predominance and decreased parasympathe...
International audienceAims: Heart failure with reduced ejection fraction (HFrEF) remains associated ...
Background: Heart failure with reduced ejection fraction (HFrEF) is characterized by activation of t...
International audienceBackground: This study demonstrated the safety and effectiveness of baroreflex...
Background: In a randomized trial, baroreflex activation therapy (BAT) improved exercise capacity, q...
Chronic heart failure is a common clinical condition characterized by persistent excessive sympathet...
Autonomic imbalance characterized by sympathetic predominance and decreased parasympathetic transmis...
Abstract Baroreflex activation therapy (BAT) is a possible adjuvant treatment for patients with hear...
AbstractObjectivesThe objective of this clinical trial was to assess the safety and efficacy of caro...
There has been significant interest in research for the development of device-based therapy as a tre...
AbstractA patient experiencing chronic New York Heart Association (NYHA) Class III heart failure wit...
Background: Prognosis in advanced heart failure with reduced ejection fraction (HFrEF) remains poor ...
The progression of heart failure with reduced ejection fraction is promoted by sympathovagal imbalan...
Heart failure is promoted by the imbalance of sympathovagal, which increased sympathetic and decreas...
Background: Baroreflex activation therapy (BAT) exerts in severe heart failure sympathoinhibitory ef...
Background: Autonomic imbalance characterized by sympathetic predominance and decreased parasympathe...
International audienceAims: Heart failure with reduced ejection fraction (HFrEF) remains associated ...
Background: Heart failure with reduced ejection fraction (HFrEF) is characterized by activation of t...
International audienceBackground: This study demonstrated the safety and effectiveness of baroreflex...
Background: In a randomized trial, baroreflex activation therapy (BAT) improved exercise capacity, q...
Chronic heart failure is a common clinical condition characterized by persistent excessive sympathet...
Autonomic imbalance characterized by sympathetic predominance and decreased parasympathetic transmis...
Abstract Baroreflex activation therapy (BAT) is a possible adjuvant treatment for patients with hear...
AbstractObjectivesThe objective of this clinical trial was to assess the safety and efficacy of caro...
There has been significant interest in research for the development of device-based therapy as a tre...